NCT06021574View on ClinicalTrials.gov

A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Healthy
Interventions
DRUG

VDJ001

a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody

DRUG

Placebo

Placebo

Trial Locations (1)

266000

the Affliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
collaborator

Beijing VDJBio Co., LTD.

INDUSTRY

lead

The Affiliated Hospital of Qingdao University

OTHER

NCT06021574 - A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody | Biotech Hunter | Biotech Hunter